Zhang Zhao-Hui, Ma Li-Wen, Song Shi-Bing, Xiu Dian-Rong, Wang Jun-Jie, Yang Xiao-Xia, Jia Yi-Mu
Cancer Centre, Peking University Third Hospital, Beijing 100083, China.
Zhonghua Zhong Liu Za Zhi. 2005 Jan;27(1):45-7.
To investigate the feasibility, reliability and therapeutic effectiveness of adjuvant chemotherapy for advanced hepatocellular carcinoma (HCC) after orthotopic liver transplantation (OLT).
The clinical data of adjuvant chemotherapy after OLT in 10 advanced HCC patients were studied retrospectively. FAP chemotherapy regimen was adopted calcium folinate (CF) 200 mg/m(2) and 5-Fluorouracil 500 mg/m(2) iv on D1 to D5, and doxorubicin 40 mg/m(2), cisplatin 30 mg/m(2) iv on D1, with 28 days as a cycle. The opportune time of chemotherapy, chemotherapy regimen, synergistic action between cytotoxic agent and immunosuppressive agent on liver and kidney and side-effects were preliminarily evaluated.
7/10 patients are surviving, with the longest survival of 32 months, and the shortest 9 months. Three patients died after operation, two at 13 months, one at 20 months after OLT, all died of metastasis. The incidence of one year survival was 9/9. During the period of chemotherapy, the side-effects of adjuvant chemotherapy were moderate.
Chemotherapy which is able to prolong the life-span of patients with advanced HCC after orthotopic liver transplantation is feasible and effective, the side-effects were mild. The choice of opportune time of chemotherapy might influence the outcome.
探讨原位肝移植（OLT）后晚期肝细胞癌（HCC）辅助化疗的可行性、可靠性及治疗效果。
回顾性研究10例晚期HCC患者OLT后辅助化疗的临床资料。采用FAP化疗方案，亚叶酸钙（CF）200mg/m²、5-氟尿嘧啶500mg/m²静脉滴注，第1至5天，阿霉素40mg/m²、顺铂30mg/m²静脉滴注，第1天，28天为1个周期。对化疗时机、化疗方案、细胞毒药物与免疫抑制剂对肝肾的协同作用及副作用进行初步评估。
10例患者中7例存活，最长存活32个月，最短9个月。3例术后死亡，2例在OLT后13个月，1例在20个月，均死于转移。1年生存率为9/9。化疗期间，辅助化疗的副作用为中度。
原位肝移植后晚期HCC患者辅助化疗能够延长患者寿命，可行且有效，副作用轻微。化疗时机的选择可能影响治疗结果。
Zotero 插件